Last10K.com

Dr Reddys Laboratories Ltd (RDY) SEC Filing 20-F Annual report for the fiscal year ending Tuesday, March 31, 2020

SEC Filings

RDY Annual Reports

20-F Annual Report June 2021
20-F Annual Report June 2020
20-F Annual Report June 2019
20-F Annual Report June 2018
20-F Annual Report June 2017
20-F Annual Report June 2016
20-F Annual Report June 2015
20-F Annual Report June 2014
20-F Annual Report July 2013

Dr Reddys Laboratories Ltd

CIK: 1135951 Ticker: RDY

View differences made from one year to another to evaluate Dr Reddys Laboratories Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dr Reddys Laboratories Ltd.

Continue

Assess how Dr Reddys Laboratories Ltd's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dr Reddys Laboratories Ltd's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Cover Page
Consolidated Income Statements
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Equity
Consolidated Statements Of Changes In Equity (Parenthetical)
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Financial Position
Agreements With Encore Dermatology, Inc.
Agreements With Encore Dermatology, Inc. (Details Textual)
Basis Of Preparation Of Financial Statements
Basis Of Preparation Of Financial Statements (Details Textual)
Basis Of Preparation Of Financial Statements (Policies)
Business Transfer Agreement With Wockhardt Limited
Business Transfer Agreement With Wockhardt Limited (Details Textual)
Cash And Cash Equivalents
Cash And Cash Equivalents (Details)
Cash And Cash Equivalents (Tables)
Collaboration Agreement With Curis, Inc.
Collaboration Agreement With Curis, Inc. (Details Textual)
Contingencies
Contingencies (Details 1)
Contingencies (Details Textual)
Contingencies (Details)
Contingencies (Tables)
Definitive Agreement With Upsher-Smith Laboratories, Llc
Definitive Agreement With Upsher-Smith Laboratories, Llc (Details Textual)
Determination Of Fair Values
Earnings Per Share
Earnings Per Share (Details 1)
Earnings Per Share (Details Textual)
Earnings Per Share (Details)
Earnings Per Share (Tables)
Employee Benefits
Employee Benefits (Details 1)
Employee Benefits (Details 10)
Employee Benefits (Details 11)
Employee Benefits (Details 12)
Employee Benefits (Details 13)
Employee Benefits (Details 14)
Employee Benefits (Details 15)
Employee Benefits (Details 16)
Employee Benefits (Details 17)
Employee Benefits (Details 2)
Employee Benefits (Details 3)
Employee Benefits (Details 4)
Employee Benefits (Details 5)
Employee Benefits (Details 6)
Employee Benefits (Details 7)
Employee Benefits (Details 8)
Employee Benefits (Details 9)
Employee Benefits (Details Textual)
Employee Benefits (Details)
Employee Benefits (Tables)
Employee Stock Incentive Plans
Employee Stock Incentive Plans (Details 1)
Employee Stock Incentive Plans (Details 2)
Employee Stock Incentive Plans (Details 3)
Employee Stock Incentive Plans (Details 4)
Employee Stock Incentive Plans (Details 5)
Employee Stock Incentive Plans (Details 6)
Employee Stock Incentive Plans (Details Textual)
Employee Stock Incentive Plans (Details)
Employee Stock Incentive Plans (Tables)
Finance Income, Net
Finance Income, Net (Details)
Finance Income, Net (Tables)
Financial Instruments
Financial Instruments (Details 1)
Financial Instruments (Details 2)
Financial Instruments (Details 3)
Financial Instruments (Details 4)
Financial Instruments (Details Textual)
Financial Instruments (Details)
Financial Instruments (Tables)
Financial Risk Management
Financial Risk Management (Details 1)
Financial Risk Management (Details 2)
Financial Risk Management (Details Textual)
Financial Risk Management (Details)
Financial Risk Management (Tables)
Goodwill
Goodwill (Details 1)
Goodwill (Details Textual)
Goodwill (Details)
Goodwill (Tables)
Impact Of Covid-19
Income Taxes
Income Taxes (Details 1)
Income Taxes (Details 2)
Income Taxes (Details 3)
Income Taxes (Details 4)
Income Taxes (Details 5)
Income Taxes (Details Textual)
Income Taxes (Details)
Income Taxes (Tables)
Inspection By The Regulatory Authority Of Bavaria, Germany
Inventories
Inventories (Details 1)
Inventories (Details)
Inventories (Tables)
Inventories - (Details Textual)
Investment In Equity Accounted Investees
Investment In Equity Accounted Investees (Details 1)
Investment In Equity Accounted Investees (Details 2)
Investment In Equity Accounted Investees (Details Textual)
Investment In Equity Accounted Investees (Details)
Investment In Equity Accounted Investees (Tables)
Loans And Borrowings
Loans And Borrowings (Details 1)
Loans And Borrowings (Details 2)
Loans And Borrowings (Details 3)
Loans And Borrowings (Details 4)
Loans And Borrowings (Details 5)
Loans And Borrowings (Details 6)
Loans And Borrowings (Details Textual)
Loans And Borrowings (Details)
Loans And Borrowings (Tables)
Merger Of Dr. Reddy's Holdings Limited Into Dr. Reddy's Laboratories Limited
Merger Of Dr. Reddy's Holdings Limited Into Dr. Reddy's Laboratories Limited (Details Textual)
Nature Of Expense
Nature Of Expense (Details)
Nature Of Expense (Tables)
Operating Leases
Operating Leases (Details Textual)
Operating Leases (Details)
Operating Leases (Tables)
Organizational Structure
Organizational Structure (Details Textual)
Organizational Structure (Details)
Organizational Structure (Tables)
Other Assets
Other Assets (Details)
Other Assets (Tables)
Other Income, Net
Other Income, Net (Details Textual)
Other Income, Net (Details)
Other Income, Net (Tables)
Other Intangible Assets
Other Intangible Assets (Details 1)
Other Intangible Assets (Details 2)
Other Intangible Assets (Details Textual)
Other Intangible Assets (Details)
Other Intangible Assets (Tables)
Other Investments
Other Investments (Details)
Other Investments (Tables)
Other Liabilities
Other Liabilities (Details)
Other Liabilities (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Details 1)
Property, Plant And Equipment (Details 2)
Property, Plant And Equipment (Details Textual)
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Provisions
Provisions (Details Textual)
Provisions (Details)
Provisions (Tables)
Related Parties
Related Parties (Details 1)
Related Parties (Details 2)
Related Parties (Details)
Related Parties (Tables)
Reporting Entity
Restructuring Of Pharmaceutical Services Business
Restructuring Of Pharmaceutical Services Business (Details Textual)
Revenue From Contracts With Customers And Trade Receivables
Revenue From Contracts With Customers And Trade Receivables (Details 1)
Revenue From Contracts With Customers And Trade Receivables (Details 2)
Revenue From Contracts With Customers And Trade Receivables (Details 3)
Revenue From Contracts With Customers And Trade Receivables (Details 4)
Revenue From Contracts With Customers And Trade Receivables (Details 5)
Revenue From Contracts With Customers And Trade Receivables (Details 6)
Revenue From Contracts With Customers And Trade Receivables (Details 7)
Revenue From Contracts With Customers And Trade Receivables (Details 8)
Revenue From Contracts With Customers And Trade Receivables (Details Textual)
Revenue From Contracts With Customers And Trade Receivables (Details)
Revenue From Contracts With Customers And Trade Receivables (Tables)
Segment Reporting
Segment Reporting (Details 1)
Segment Reporting (Details 2)
Segment Reporting (Details 3)
Segment Reporting (Details 4)
Segment Reporting (Details 5)
Segment Reporting (Details 6)
Segment Reporting (Details 7)
Segment Reporting (Details Textual)
Segment Reporting (Details)
Segment Reporting (Tables)
Share Capital
Share Capital (Details 1)
Share Capital (Details Textual)
Share Capital (Details)
Share Capital (Tables)
Significant Accounting Policies
Significant Accounting Policies (Details 1)
Significant Accounting Policies (Details 2)
Significant Accounting Policies (Details Textual)
Significant Accounting Policies (Policies)
Significant Accounting Policies (Tables)
Subsequent Events
Trade And Other Payables
Trade And Other Payables (Details)
Trade And Other Payables (Tables)
Trade And Other Receivables
Trade And Other Receivables (Details 1)
Trade And Other Receivables (Details Textual)
Trade And Other Receivables (Details)
Trade And Other Receivables (Tables)
Update On The Warning Letter From The U.S. Fda
Ticker: RDY
CIK: 1135951
Form Type: 20-F Annual Report
Accession Number: 0001575872-20-000145
Submitted to the SEC: Mon Jun 15 2020 3:32:36 PM EST
Accepted by the SEC: Mon Jun 15 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rdy/0001575872-20-000145.htm